Cilazapril

Cilazapril

Clinical data
ATC code	C09AA08 (WHO)
Identifiers
IUPAC name (5S,8S)-5-{[(1S)-1-ethoxycarbonyl-3-phenyl-propyl] amino}-6-oxo-1,7-diazabicyclo[5.4.0]undecane-8- carboxylic acid
CAS Number	92077-78-6
PubChem CID	56330
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H33N3O6
Molar mass	435.514 g/mol

WikiDoc Resources for Cilazapril
Articles
Most recent articles on Cilazapril Most cited articles on Cilazapril Review articles on Cilazapril Articles on Cilazapril in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cilazapril Images of Cilazapril Photos of Cilazapril Podcasts & MP3s on Cilazapril Videos on Cilazapril
Evidence Based Medicine
Cochrane Collaboration on Cilazapril Bandolier on Cilazapril TRIP on Cilazapril
Clinical Trials
Ongoing Trials on Cilazapril at Clinical Trials.gov Trial results on Cilazapril Clinical Trials on Cilazapril at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cilazapril NICE Guidance on Cilazapril NHS PRODIGY Guidance FDA on Cilazapril CDC on Cilazapril
Books
Books on Cilazapril
News
Cilazapril in the news Be alerted to news on Cilazapril News trends on Cilazapril
Commentary
Blogs on Cilazapril
Definitions
Definitions of Cilazapril
Patient Resources / Community
Patient resources on Cilazapril Discussion groups on Cilazapril Patient Handouts on Cilazapril Directions to Hospitals Treating Cilazapril Risk calculators and risk factors for Cilazapril
Healthcare Provider Resources
Symptoms of Cilazapril Causes & Risk Factors for Cilazapril Diagnostic studies for Cilazapril Treatment of Cilazapril
Continuing Medical Education (CME)
CME Programs on Cilazapril
International
Cilazapril en Espanol Cilazapril en Francais
Business
Cilazapril in the Marketplace Patents on Cilazapril
Experimental / Informatics
List of terms related to Cilazapril

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cilazapril is an angiotensin-converting enzyme inhibitor (ACE inhibitor) used for the treatment of hypertension and congestive heart failure. It is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these are available in the United States as of May 2010.

Of the eight possible stereoisomers, only the all-S form is medically viable.